Hasil Pencarian - Revathi Ananthakrishnan

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    The Forces Behind Cell Movement

    The Forces Behind Cell Movement oleh Revathi Ananthakrishnan, Allen Ehrlicher

    Diterbitkan 2007-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Pharmacological modeling and biostatistical analysis of a new drug

    Pharmacological modeling and biostatistical analysis of a new drug oleh Revathi Ananthakrishnan, Philimon Gona

    Diterbitkan 2010-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy

    2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy oleh Revathi Ananthakrishnan, Stephanie Green, Daniel Li, Michael LaValley

    Diterbitkan 2019-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials

    Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials oleh Revathi Ananthakrishnan, Stephanie Green, Daniel Li, Michael LaValley

    Diterbitkan 2018-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Systematic comparison of the statistical operating characteristics of various Phase I oncology designs

    Systematic comparison of the statistical operating characteristics of various Phase I oncology designs oleh Revathi Ananthakrishnan, Stephanie Green, Mark Chang, Gheorghe Doros, Joseph Massaro, Michael LaValley

    Diterbitkan 2017-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    An overview of the BOIN design and its current extensions for novel early-phase oncology trials

    An overview of the BOIN design and its current extensions for novel early-phase oncology trials oleh Revathi Ananthakrishnan, Ruitao Lin, Chunsheng He, Yanping Chen, Daniel Li, Michael LaValley

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

    Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma oleh Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano‐Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

    Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study oleh Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani

    Diterbitkan 2017-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: